Overview

Study Evaluating Patients With Cystinuria and Efficacy and Safety Exploratory Study in the Youngest Children

Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
This is a multicentre, randomized, controlled versus placebo, double-blinded, 4 parallel arms, dose-ranging main study, to evaluate the efficacy, safety and tolerability and acceptability of repeated doses of ADV7103, after 7 days of treatment, in patients with cystinuria, and an efficacy and safety exploratory study in the youngest children.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Advicenne Pharma